Compare NVR Inc. Common Stock (NVR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NVR Inc. Common Stock vs Zoetis Inc — how do they compare? NVR Inc. Common Stock trades at $5,798 (market cap $15.28B), while Zoetis Inc trades at $75.98 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 2× NVR Inc. Common Stock's market cap, and Zoetis Inc pays a 2.82% dividend while NVR Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NVR Inc. Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| NVR | ZTS | |
|---|---|---|
Market Cap | $15.28B | $31.11B |
Volume | 53,948 | 2,515,954 |
Sector | Consumer Cyclical | Health |
52-Week High | $8.10K | $147.53 |
52-Week Low | $5.56K | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $15.18B | $38.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.
ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
